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Background: Glycogen synthase kinase-3 (GSK-3) is a constitutively active kinase that regulates multiple signalling
proteins and transcription factors involved in a myriad of cellular processes. The kinase acts as a negative regulator
in β-catenin signalling and is critically involved in the smad pathway. Activation of both pathways may contribute
to pulmonary features of chronic obstructive pulmonary disease (COPD).
Methods: In the present study, we investigated the effect of the selective GSK-3 inhibitor SB216763 on pulmonary
pathology in a guinea pig model of lipopolysaccharide (LPS)-induced COPD. Guinea pigs were instilled intranasally
with LPS or saline twice weekly for 12 weeks and pre-treated with either intranasally instilled SB216763 or
corresponding vehicle 30 min prior to each LPS/saline challenge.
Results: Repeated LPS exposures activated β-catenin signalling, primarily in the airway epithelium and submucosa.
LPS also induced pulmonary inflammation and tissue remodelling as indicated by inflammatory cell influx,
increased pulmonary fibronectin expression and enhanced small airway collagen content. Inhibition of GSK-3 by
SB216763 did not affect LPS-induced inflammatory cell influx, but prevented the small airway remodelling and,
unexpectedly, inhibited the activation of β-catenin in vivo. LPS or SB216763 treatment had no effect on the airway
smooth muscle content and alveolar airspace size. However, GSK-3 inhibition prevented LPS-induced right ventricle
hypertrophy.
Conclusions: Our findings indicate that GSK-3 inhibition prevents LPS-induced pulmonary pathology in guinea
pigs, and that locally reduced LPS-induced β-catenin activation appears in part to underlie this effect.Introduction
Glycogen synthase kinase-3 (GSK-3) is a ubiquitously
expressed serine/threonine kinase, occurring in the two
closely related isoforms GSK-3α and GSK-3β which share
high homology in their kinase domains [1-3]. Originally,
GSK-3 was discovered for its role in glucose metabolism
by regulating glycogen synthase activity [3,4]. Over the
years, interest in GSK-3 signalling has increased as it* Correspondence: r.gosens@rug.nl
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reproduction in any medium, provided the orbecame apparent that this kinase regulates various physio-
logical pathways involved a wide array of processes, in-
cluding protein synthesis, cell differentiation, apoptosis
and cell survival [5,6]. Currently, over fifty putative sub-
strates have been identified including structural proteins,
various intracellular signalling intermediates and tran-
scription factors [6]. For instance, GSK-3 is critically in-
volved as a negative regulator in β-catenin signalling and
in the regulation of smad-dependent signalling [5,6]. Both
these pathways are important in developmental processes
and may be activated during pathological conditions in
the lungs [7-10].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mary kinase that regulates cellular expression of the
transcriptional co-activator β-catenin by phosphoryl-
ation, thereby targeting it for proteasomal degradation
[11]. In pulmonary fibroblasts, we recently demonstrated
that the pro-fibrotic mediator transforming growth factor-β
(TGF-β) induces an inhibitory phosphorylation of GSK-3
and activates β-catenin signalling, which in turn con-
tributed to myofibroblast differentiation and extracellu-
lar matrix deposition by these cells [12]. Interestingly,
β-catenin activation and extracellular matrix deposition
were enhanced in fibroblasts of individuals with chronic
obstructive pulmonary disease (COPD) [12].
Despite its inhibitory role in β-catenin signalling, GSK-3
is required for fibrosis in mice [13]. In line with this, we
have shown in human pulmonary fibroblasts that GSK-3
is required for myofibroblast differentiation and matrix
protein expression [14]. Mechanistically, this is explained
by activation of cyclic AMP response element binding
protein (CREB) signalling in response to GSK-3 inhibition,
which can attenuate smad-dependent transcriptional re-
sponses. It appears therefore that GSK-3 inhibition plays a
dual role in pathological tissue remodelling. On one hand,
GSK-3 is the main negative regulator of β-catenin of
which increased activation is associated with fibroproli-
ferative diseases, whereas on the other hand GSK-3 inhib-
ition may attenuate smad-dependent gene transcription
and fibrotic responses. This dual role may be tightly con-
trolled by the subcellular localization of GSK-3, as only
the GSK-3 pool that is associated with the multi-protein
destruction complex consisting of axin, casein kinase I
and APC is involved in β-catenin signalling [15,16].
In the present study, we investigated the effect of
GSK-3 inhibition on β-catenin activation, inflammation
and matrix protein expression in response to lipopolysac-
charide (LPS)-, using the selective inhibitor 3-(2,4-dichlor-
ophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione
(SB216763). LPS is an endotoxin in the outer membrane
of gram negative bacteria that is present as a contaminant
in environmental pollution, organic dusts and cigarette
smoke, which are all factors that have been associated
with COPD development [17,18]. Furthermore, bacterial
endotoxins may contribute to COPD exacerbations [19].
Accordingly, we and others have previously demonstrated
that LPS can induce pulmonary and extrapulmonary pa-
thological features resembling COPD pathophysiology in
various animal models [20,21].Materials and methods
Animals
Outbred, male, specified pathogen-free Dunkin Hartley
guinea pigs (Harlan, Heathfield, United Kingdom) were
used. All protocols describes in this study were approvedby the University of Groningen Committee for Animal
Experimentation.
Experimental protocol
Thirty-six guinea pigs were randomly assigned to four
experimental groups, composed of vehicle treated, saline
challenged (n = 9); vehicle treated; LPS-challenged (n = 9),
SB216763 treated, saline challenged (n = 9) and SB216763
treated; LPS-challenged (n = 9). Guinea pigs were treated
twice weekly for 12 consecutive weeks by intranasal instil-
lation of 100 μL SB216763 (2 mM in 10% v/v DMSO in
sterile saline) or vehicle (10% DMSO v/v in sterile saline).
After the intranasally instilled solution was aspirated, the
animals were kept in an upright position for an additional
2 minutes, to allow sufficient spreading of the fluid through-
out the lungs. Thirty minutes after the instillations of
SB216763 or vehicle, the animals were intranasally in-
stilled with 100 μL LPS (10 mg/ml in sterile saline) or ster-
ile saline. We have previously confirmed the suitability of
these protocols for efficient pulmonary delivery of intrana-
sally instilled solutions using, among others, Evan’s Blue
dye as a control [20]. Twenty four hours after the last in-
stillation, the guinea pigs were killed by experimental con-
cussion, followed by rapid exsanguination. The heart and
lungs of each animal were resected and kept on ice for im-
mediate further processing.
Tissue processing and histological analyses
The left lung lobe was inflated and fixed with formalin
at a constant pressure of 25 cm H2O for 24 hours. The
formalin fixed lungs were embedded in paraffin and sub-
sequently cut in tissue-sections of 4 μm. The mean lin-
ear intercept (LMI), a measure for alveolar airspace size,
was determined in tissue-sections stained with haema-
toxylin and eosin. The LMI was determined as described
previously [20], by using 20-25 photo-microscopic im-
ages (magnification 200×) per animal. The LMI analysis
was performed twice by two individuals in a blinded
manner. For evaluation of airway collagen, the tissue-
sections (4 μm) were stained with Sirius Red and coun-
terstained with haematoxylin. Airways were digitally
photographed (100-200 × magnification) and using Ima-
geJ software, each image was split into RGB channels.
The green channel images were used for further analysis
and converted to binary images using the threshold
function setting the threshold value identical for all im-
ages. The positively stained area in the airway wall, from
adventitial border to the basement membrane, was digit-
ally quantified in at least 2 airways per animal. The air-
way collagen area was then normalized to the squared
basement membrane length. The analysis was done in a
blinded manner.
The upper right lung lobe was immediately frozen in li-
quid nitrogen after resection. Transverse frozen sections
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chemical analysis. The smooth muscle area was identified
using immunohistochemical staining for smooth-muscle-
specific myosin heavy chain (sm-MHC; dilution 1:100,
Neomarkers, Fremont, CA, USA). To identify granulocytes,
sections were stained with diaminobenzidine (0.3 mg/ml).
The specific primary antibodies were visualized by using
horseradish peroxidase (HRP)-linked secondary antibodies,
followed by a diaminobenzidine staining (0.1 mg/ml for
sm-MHC). Sections were counter stained with haematoxy-
lin. The airways within sections were digitally photographed
(200 × magnification) and classified as cartilaginous or
non-cartilaginous. All immunohistochemical analyses were
performed using ImageJ software. Per animal, at least 2
lung sections were analysed per staining, each section con-
taining 2-5 airways. The sm-MHC positively stained area
was digitally quantified and normalized to the squared
basement membrane length. The number of inflammatory
cells within 50 μm distance from the airway lumen was
quantified and expressed relative to basement membrane
length. All analyses were done in a blinded manner.
For identification of activated β-catenin, sections were
stained for non-phosphorylated β-catenin (dilution 1:50;
Active β-catenin; ABC clone 8E7, Millipore, Amsterdam,
The Netherlands). The specific primary antibodies were
visualized by using Cy3-conjugated secondary antibodies
and analysed using an Olympus AX70 microscope equipped
with digital image capture system (ColorView Soft System
with Olympus U CMAD2 lens). Sections were counter
stained with Hoechst 3342.
Immunoblotting
The lower right lung lobe was used for protein analysis
by immunoblotting. Lung homogenates were prepared
by pulverizing the frozen tissue under liquid nitrogen,
after which 300 mg tissue was sonicated in 1 ml of ice-
cold radio-immunoprecipation (RIPA) buffer supple-
mented with protease and phosphatase inhibitors (com-
position: Tris–HCl 50.0 mM, NaCl 150.0 mM, EDTA
1.0 mM, Na3VO4 1.0 mM, NaF 1.0 mM, Na-deoxycholate
0.25% and 1% Igepal (NP-40), supplemented with 5 mM
β-glycerophosphate, 10 μg/ml leupeptin, 10 μg/ml aproti-
nin and 10 μg/ml pepstatin; at pH 7.4).
Equal amounts of protein (50 μg/lane) were subjected
to electrophoresis on polyacrylamide gels, transferred to
nitrocellulose membranes and analysed for the proteins
of interest using specific primary and HRP-conjugated
secondary antibodies. By using enhanced chemilumines-
cence reagents, bands were recorded in the G:BOX
iChemi gel documentation system equipped with GeneS-
nap image acquisition software (Syngene; Cambridge;
UK). Band intensities were quantified by densitometry
using GeneTools analysis software (Syngene; Cambridge;
UK).Antibodies and reagents
The mouse anti-smooth-muscle-specific myosin heavy
chain (sm-MHC) antibody was from Neomarkers (Fremont,
CA, USA). Horseradish peroxidase (HRP)-conjugated goat
anti-mouse antibody, HRP-conjugated goat anti-rabbit
antibody, HRP-conjugated rabbit anti-goat antibody and
lipopolysaccharides (LPS) from Escherichia coli (055:B5)
were purchased from Sigma (St. Louis, MO, USA). Cy3
conjugated secondary antibodies were obtained from Jack-
son ImmunoResearch (West Grove PA, USA). Mouse
anti-GSK-3 antibody, goat anti-fibronectin (C20) antibody
and mouse anti-glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) antibody were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit anti-
phospho-Ser9/21-GSK-3 antibody was from Cell Signaling
Technology (Beverly, MA, USA). Mouse anti-total β-
catenin antibody was from BD Biosciences (San Jose, CA,
USA). Mouse anti-non-Ser37/Thr41-phosphorylated-β-ca-
tenin antibody (clone 8E7) was from Millipore (Amsterdam,
the Netherlands). The selective GSK-3 inhibitor 3-(2,4-
Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-
dione (SB216763) was obtained from Tocris Cookson
(Bristol, UK). Recombinant human TGF-β1 was from
R&D systems (Abingdon, UK). All other chemicals were
of analytical grade.
Statistical analysis
Data represent means ± S.E.M, from n separate experi-
ments. Statistical significance of differences was evaluated
by one-way or two-way ANOVA, where appropriate,
followed by a Newman-Keuls multiple comparison test.
Differences were considered to be statistically significant
when p < 0.05.
Results
Effect of repeated LPS instillation and GSK-3 inhibition on
extracellular matrix turnover
First, we evaluated the effects of repeated LPS instillation
and SB216763 treatment on airway fibrosis. To this aim,
the lungs of the guinea pigs were analysed for the expres-
sion of the extracellular matrix proteins fibronectin and
collagen. Repeated LPS instillation caused a significant up
regulation of fibronectin expression in whole lung homog-
enates (Figure 1A). Pulmonary fibronectin expression ap-
peared to be up regulated by GSK-3 inhibition; however,
this was not statistically significant. Interestingly, fibronec-
tin expression after repeated LPS instillation and treat-
ment with SB216763 was similar to the effect of treatment
with just SB216763. Statistical analysis revealed a trend
towards a negative interaction between the effect of
SB216763 and of LPS (p = 0.052, determined by two-way
ANOVA).
Figure 1 Effect of repeated intranasal LPS challenge and treatment with the selective GSK-3 inhibitor SB216763 on extracellular matrix
deposition in the lung. (A) Expression of fibronectin was evaluated in whole lung homogenates 24 hours after the last challenge by
immunoblotting using specific antibodies. Equal protein loading was verified by the analysis of GAPDH. Effects of repeated LPS challenge and
SB216763 treatment on fibronectin expression were quantified by densitometry, representing mean ± s.e.m. of 9 animals per group. (B)
Histological staining of the extracellular matrix protein collagen using Sirius Red. The non-cartilaginous airways were digitally photographed (100-
200 × magnification) and analysed by using ImageJ software. Effects of repeated LPS challenge and SB216763 treatment on airway collagen
expression were quantified, representing mean ± s.e.m. of 9 animals per group. (C) The mean linear intercept (LMI), a measure for alveolar
airspace size, was determined by staining the tissue-sections with haematoxylin and eosin. Data represent means ± s.e.m. of 9 animals per group.
**p < 0.01 compared to control group and #p < 0.05 compared to LPS treated animals. Scale bar = 200 μm.
Baarsma et al. Respiratory Research 2013, 14:113 Page 4 of 10
http://respiratory-research.com/content/14/1/113Next, we determined the expression of collagen in non-
cartilaginous airways by quantitative analysis of Sirius Red
staining in these airways. Similar to the increase in pul-
monary fibronectin expression, repeated LPS instillation
increased small airway collagen content by 1.88 ± 0.18
fold compared to the average of the saline treated ani-
mals (Figure 1B). Topical treatment of the airways with
intranasally instilled SB216763 fully inhibited the LPS-
induced increase in collagen deposition in the walls of
the small airways, whereas the selective GSK-3 inhibitor
did not affect the collagen content in saline treated ani-
mals (Figure 1B).Emphysema, a pathological feature defined by the loss of
the alveolar structure and increased parenchymal airspaces
may be caused by tissue destruction in combination with
an impaired repair process within the parenchyma [17].
To evaluate the effect of GSK-3 inhibition on the size of
the alveolar airspaces, LMI was determined in paraffin-
embedded lung sections. Repeated LPS instillation for
12 weeks did not significantly affect the LMI and, more
importantly, inhibition of GSK-3 by SB216763 did not
affect the size of the alveolar airspaces in either saline- or
LPS-instilled animals (Figure 1C). Collectively, this indi-
cates that repeated instillation of LPS induces alterations
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hibition of GSK-3 is beneficial in attenuating small airway
fibrosis without affecting alveolar airspace size.
Effects of repeated LPS instillation and GSK-3 inhibition
on airway smooth muscle content
Published findings indicate that growth factor induced
inhibition of GSK-3 promotes airway smooth muscle
cell proliferation and hypertrophy [22,23]. Therefore,
the airway smooth muscle content in cartilaginous and
non-cartilaginous airways was determined by staining
transverse frozen lung sections for the specific marker
smooth-muscle myosin heavy chain (sm-MHC). Represen-
tative photomicrographs of serial lung sections containing
the larger (cartilaginous) and small (non-cartilaginous)
airways are shown in Figure 2. Morphometric analysis








































Figure 2 Repeated LPS instillation and pharmacological inhibition of
Immunohistological analysis of sm-MHC positive area in (A) large (cartilagin
challenge and SB216763 treatment on airway smooth muscle sm-MHC exp
per group. Scale bar = 200 μm.16763 treatment affected the smooth muscle content in
either the cartilaginous or the non-cartilaginous airways
(Figure 2).Effects of repeated LPS instillation and GSK-3 inhibition
on right ventricle hypertrophy
A well-known co-morbidity in COPD is the occurrence
of pulmonary hypertension resulting in alterations in
structure and function of the right ventricle of the heart
[24]. Repeated LPS challenge induced right ventricle
hypertrophy in the guinea pigs as indicated by a signifi-
cant 1.48 ± 0.13-fold increase in the ratio of right ven-
tricle weight over total heart weight compared to saline
treated animals (Figure 3). SB216763 fully prevented the
LPS-induced right ventricle hypertrophy; whereas the se-
lective GSK-3 inhibitor did not have an effect in saline






































GSK-3 by SB216763 do not affect airway smooth muscle content.
ous) and (B) small (non-cartilaginous) airways. Effects of repeated LPS








































Figure 3 Right ventricle hypertrophy after repeated intranasal
LPS instillation is attenuated by GSK-3 inhibition. Effect of
repeated LPS instillation and GSK-3 inhibition by SB216763 on right
ventricle hypertrophy. Effects of repeated LPS challenge and
SB216763 treatment on size of right ventricle were quantified as right
ventricle weight over total heart weight, representing mean ± s.e.m. of
9 animals per group. **p < 0.01 compared to control group and
#p < 0.05 compared to LPS treated animals.
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inflammation
We previously reported that repeated LPS exposures in-
duce an increase in infiltrated inflammatory cells in the
airways, consisting mostly of neutrophils [20]. Also,
GSK-3 inhibition was previously reported to have anti-
inflammatory effects in vitro and in vivo. Indeed, in the
current study, repeated LPS challenges induced an in-
crease in peribronchial inflammation, which was most
profound in the non-cartilaginous airways. Surprisingly
however, treatment with SB216763 did not affect the
presence of inflammatory cells in and surrounding the
airway wall in saline challenged animals and had no ef-
fect on the peribronchial inflammation seen after LPS
challenge (Figure 4). This suggests that the effects of
GSK-3 inhibition on airway fibrosis were not via anti-
inflammatory effects in this model. Further evaluation of
the inflammatory response was not possible unfortu-
nately due to the lack of species cross-reactivity of com-
mercially available tools.
Effects of repeated LPS instillation and GSK-3 inhibition
on β-catenin activation
We aimed to gain more mechanistic insight into the re-
duced airway fibrosis we observed after GSK-3 inhibition.
We investigated the activation of β-catenin signalling in
whole lung homogenates in response to repeated intrana-
sal instillation of LPS. The endotoxin LPS clearly induced
the expression of active, non-Ser37/Thr41-phosphorylated
β-catenin in whole lung homogenates compared to the sa-
line treated animals (Figure 5A and B). Fibrotic changes in
the lungs may be due to activation of β-catenin signalling[8,12,25]. Therefore, we analysed the correlation between
active β-catenin expression and the amount of fibronectin
in whole lung homogenate (Figure 5D). A significant lin-
ear correlation (R = 0.552; p < 0.001) exists between the
presence of active β-catenin and pulmonary fibronectin
expression (for both parameters the average of vehicle/
saline treated animals was set to 100%). Immunofluores-
cence analysis revealed that activated β-catenin was
expressed primarily in the airway epithelium and the
airway smooth muscle (Figure 5E).
The selective GSK-3 inhibitor SB216763 did not signifi-
cantly affect the expression of the active form of β-catenin
compared to that in saline treated animals (Figure 5A and
B). Unexpectedly however, selective inhibition of GSK-3
attenuated the LPS-induced expression of β-catenin to
levels comparable to those in saline treated animals
(Figure 5A, B and E). GSK-3 is considered a constitu-
tively active kinase, which is inhibited upon serine phos-
phorylation (i.e. ser9 on GSK-3β and ser21 on GSK-3α).
The phospho-serines act as a pseudo-substrate for the
kinase itself, thereby competitively preventing the acces-
sibility of other substrates to the active site of the kinase
[6]. LPS did not induce the inhibitory serine phosphoryl-
ation of GSK-3 in whole lung homogenates. Treatment
with SB216763 had no effect on GSK-3 phosphorylation
either in saline or LPS-exposed animals (Figure 5A and C).
Discussion
In this study, we demonstrate that glycogen synthase
kinase-3 (GSK-3) signalling significantly contributes to the
development of pathological features in response to re-
peated LPS exposures in guinea pigs. Repeated intranasal
LPS instillation induced the activation of β-catenin signal-
ling and remodelling with an increase in pulmonary fibro-
nectin expression and enhanced collagen content in the
smaller, non-cartilaginous airways. Unexpectedly, phar-
macological inhibition of GSK-3 by topical administration
of the small molecule inhibitor SB216763 prevented the
LPS-induced activation of β-catenin signalling. Further,
in vivo treatment with SB216763 prevented the small air-
way remodelling, and right ventricle hypertrophy, and had
no detrimental effect on alveolar airspace size or airway
smooth muscle content. Collectively, these data indicate
that GSK-3 plays a paradoxical dual role in β-catenin sig-
nalling and may be a beneficial therapeutic target.
Airway fibrosis is a characteristic feature of COPD, which
contributes to airway wall thickening and airflow limitation
[26]. We demonstrate that repeated LPS instillation re-
sulted in increased expression of the extracellular matrix
proteins fibronectin and collagen. The pulmonary expres-
sion of fibronectin significantly correlated to the protein
level of activated β-catenin, which was predominantly
present in the epithelial cells lining the airways and









































Figure 4 GSK-3 inhibition does not inhibit LPS-induced pulmonary inflammation. Effect of repeated LPS instillation and GSK-3 inhibition by
SB216763 on inflammatory cell infiltration in the airways. Cells within 50 μm of the basement membrane were quantified and expressed relative
to basement membrane length, representing mean ± s.e.m. of 9 animals per group. *p < 0.05 compared to control group. Scale bar = 200 μm.
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content in the non-cartilaginous airways. We and others
have previously shown that pulmonary fibronectin expres-
sion is regulated by canonical WNT/β-catenin signalling
[25,27,28]. Activation of β-catenin is important in normal
wound healing, however aberrant activation of this tran-
scriptional co-activator has been associated with various
fibroproliferative diseases, including chronic lung diseases
[7,8,29]. β-Catenin may directly be responsible for the
transcription of fibronectin, via its interaction with T-cell-
factor/lymphoid enhancer factor (TCF/LEF) transcription
factors [27]. Furthermore, β-catenin may also increase fi-
bronectin expression in an indirect manner by up regulat-
ing TGF-β expression and subsequent activation of smad
signalling [30]. Thus, β-catenin appears to play an import-
ant role in airway fibrosis, including that seen in our ani-
mal model.
Paradoxically, pharmacological inhibition of GSK-3 by
topical administration of SB216763 prevented the LPS-
induced collagen and fibronectin expression but had noeffect on the inflammatory response suggesting that this
is a direct effect on matrix protein expression. These
findings are paradoxical as GSK-3 is a negative regulator
of β-catenin expression in fibroblasts [12]. Furthermore,
GSK-3 is a well-known suppressor of epithelial-mesenchymal
transition as GSK-3 phosphorylates the transcription factor
Snail, targeting it for proteasomal degradation, and allow-
ing transcription of adherens junction proteins such as E-
cadherin in epithelial cells [31]. These paradoxical findings
are nonetheless consistent with those of Kneidinger and
colleagues, who showed that intraperitoneal administra-
tion of the GSK-3 inhibitor LiCl was capable of decreasing
pulmonary collagen expression in a murine model of
elastase-induced emphysema [32]. Furthermore, the se-
lective GSK-3 inhibitor SB216763 has been demonstrated
to attenuate pulmonary fibrosis induced by bleomycin
[13]. In the same study it was shown that attenuation of
the fibrogenic processes upon GSK-3 inhibition occurred
independently of the inflammatory response, suggesting a
direct effect of GSK-3 on cells regulating the fibrotic
Figure 5 Activation of β-catenin in response to repeated intranasal LPS challenge is prevented by treatment with the selective GSK-3
inhibitor SB216763. (A) Expression of active β-catenin, phosphorylated GSK-3 (ser9/21 GSK-3) and total GSK-3 was evaluated in whole lung
homogenates 24 hours after the last challenge by immunoblotting using specific antibodies. Equal protein loading was verified by the analysis of
GAPDH. (B,C) Responses of repeated LPS challenge and SB216763 treatment on active β-catenin expression (B) and GSK-3 phosphorylation (C)
were quantified by densitometry, representing mean ± s.e.m. of 9 animals per group. (D) Correlation between pulmonary expression of
fibronectin (data from Figure 1) and active β-catenin in all guinea pigs. R = 0.552; p < 0.001. (E) Immunofluorescence analysis of active β-catenin
(red) in large airways counterstained with Hoechst 3342 to stain nuclei (blue). *p < 0.05 compared to control group and #p < 0.05 compared to
LPS treated animals.
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viously shown that GSK-3 inhibition or silencing of the
kinase by siRNA attenuates TGF-β induced fibronectin
and sm-α-actin expression in pulmonary fibroblasts [14].
In that study, pharmacological inhibition of GSK-3 by
SB216763 resulted in an increase in ser133 cyclic adenosine
3′5′ monophosphate (cAMP) response element binding
protein (CREB) phosphorylation in pulmonary fibroblasts,
which was associated with inhibition of functional TGF-β
signalling [14]. In various cells it has been demonstrated
that smad-dependent signalling can be functionally antag-
onized by activation of CREB, which provides an explan-
ation for the inhibitory effects of SB216763 on airway
fibrosis [33-36]. Unfortunately, due to lack of availability
of phospho-serine133 specific antibodies against guinea
pig CREB, it was not possible to determine the phosphor-
ylation status of CREB in our studies. Nonetheless, GSK-3
mediated regulation of CREB and smad-dependent sig-
nalling appears a plausible explanation for the paradox-
ical inhibition of LPS induced β-catenin expression and
subsequent matrix protein production by SB216763 as we
did not observe anti-inflammatory effects of SB216763 inour experiments. Growth factors, including TGF-β, re-
gulate cellular β-catenin expression by smad mediated
gene-transcription in addition to GSK-3 dependent post-
translational effects on β-catenin protein stability [37,38].
In support, TGF-β induced β-catenin expression in pul-
monary fibroblasts, and this was attenuated by either
SB216763 or by smad3 inhibition using SIS3 (data not
shown). In further support, a recent study indicated that
hyperoxia induced β-catenin expression by pulmonary
vessels could be repressed by SB216763 treatment in rats
[39]. Collectively, these data indicate that in vivo activation
of β-catenin signalling is associated with an increase in
the pulmonary extracellular matrix deposition, whereas
selective inhibition of GSK-3 prevents this LPS-induced
process.
In addition to fibrosis, increased smooth muscle content
in the airways may be part of the airway remodelling, con-
tributing to COPD pathophysiology [40]. It is important
to note, that alterations in airway smooth muscle content
are observed in individuals with very severe COPD only.
In our guinea pig model, we did not observe alterations in
smooth muscle content, as determined by sm-MHC po-
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(non-cartilaginous) airways, which is in agreement with
previously published findings in this model [20]. Of inter-
est is that smooth muscle mass did not change in response
to GSK-3 inhibition either. Published findings indicate
that growth factor induced inhibition of GSK-3 promotes
airway smooth muscle cell proliferation and hypertrophy
[22,23]. Further, airway smooth muscle growth in re-
sponse to allergen exposure correlates with GSK-3 in-
activation in airway smooth muscle in mice [41]. The
observation that pharmacological inhibition of GSK-3
using SB216763 is not sufficient to promote airway
smooth muscle growth is therefore reassuring and pro-
vides further support for the suitability of GSK-3 as a
drug target.
COPD is a disease with significant extrapulmonary ef-
fects that contribute to disease severity [24]. Therefore, we
investigated right ventricle size in response to repeated
LPS instillation. LPS induced right ventricle hypertrophy,
which was fully prevented by SB216763. This indicates
that GSK-3 contributes to this pathological feature and
therefore possibly to the development of pulmonary hy-
pertension. Although investigations on the underlying
mechanisms were not part of the design of the current
study, it is well known that both vascular remodelling and
functional changes in the vessel wall may lead to increased
resistance in the pulmonary vasculature, causing pulmon-
ary hypertension [24]. We have previously analysed vascu-
lar remodelling extensively in the LPS-challenged guinea
pig [20], but consistently found no effect on the thickness
of the pulmonary artery medial area and pulmonary arteri-
ole wall area. This suggests that the ventricle remodeling
is not due to pulmonary vascular remodelling, but due to
functional changes in pulmonary vascular constriction, for
example as a result of hypoxia [20].
Taken together, this study demonstrates that topical
application of the selective GSK-3 inhibitor SB216763 is
capable of preventing pulmonary remodelling effects in
a guinea pig model of COPD. Although the exact mech-
anism(s) underlying these effects remains to be estab-
lished, we propose that the anti-remodelling properties
of the drug may be related to CREB dependent attenu-
ation of smad activation. In conclusion, our findings sug-
gest that inhibition of GSK-3 may provide a novel means
for the treatment of chronic airway diseases, such as
COPD.
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